查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813944

美國腫瘤分子診斷市場規模、佔有率和趨勢分析報告：按類型、產品、技術、地區和細分市場預測，2025-2033 年

U.S. Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 136 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國腫瘤分子診斷市值將達到 14.9 億美元，2025 年至 2033 年的複合年成長率將達到 5.2%。

推動市場發展的關鍵因素包括定序技術的快速發展（例如，從 Sanger 到 NGS 的轉變以及奈米孔和 SMRT 等長讀平台的採用），這些技術可以實現高通量和全面的基因組分析。標靶治療治療和泛癌生物標記（例如 HER2、EGFR 和 NTRK 融合）的日益普及正在推動對伴隨診斷的需求。液態切片/ctDNA 檢測等微創方法的日益普及有助於即時疾病監測和早期檢測。 ddPCR 和 RNA-seq 等高靈敏度平台的進步提高了對低頻突變和融合的檢測，而 AI/ML 整合則增強了腫瘤起源預測。從肺腺癌到乳癌等多種腫瘤類型的臨床效用的提高，再加上大型面板 CDx 檢測（例如 FoundationOne CDx、MSK-IMPACT）獲得監管機構的核准，進一步推動了市場成長。

美國腫瘤分子診斷 (MDx) 市場正經歷強勁成長勢頭，這得益於技術的快速進步、精準醫療與常規癌症治療的日益融合、支付方報銷範圍的擴大以及經臨床檢驗的生物標記的穩步成長。過去十年，該市場已從桑格測序等單基因、低通量檢測發展到全面的高通量新一代定序 (NGS) 平台，該平台能夠在單一工作流程中檢測各種突變、融合、拷貝數變異和微衛星不穩定性。這項技術轉變縮短了周轉時間並提高了靈敏度，使臨床醫生能夠更快地做出直接影響患者預後的治療決策。

最顯著的技術促進因素之一是快速、全自動平台的採用，例如 Biocartis 的 Idylla 系統。該系統自 2015 年在美國推出以來，穩步擴展了其腫瘤檢測產品組合。 Idylla KRAS 突變檢測（2016 年在美國推出）和 EGFR 突變檢測（2017 年在美國推出）可直接從 FFPE 組織中獲得當天的生物標記結果，無需複雜的檢測基礎設施。最近，Idylla 基因融合檢測 (GeneFusion Assay) 於 2023 年在美國推出，可檢測非小細胞肺癌 (NSCLC) 中的 ALK、ROS1、RET 和 NTRK 基因融合以及 MET 外顯子 14 跳躍突變，檢測時間不到 3 小時。在 USCAP 2025 年會（2025 年 3 月 22 日至 27 日）上，包括紀念斯隆凱特琳癌症中心和 MD 安德森癌症中心在內的多家獨立研究機構證實，Idylla™ 檢測試劑盒與 NGS 在 KRAS、EGFR 和 BRAF 突變檢測方面具有高度一致性。該平台能夠快速檢測通常會被丟棄的細胞學上清液和細針抽吸檢體，從而擴大了可檢測檢體的範圍，凸顯了其在加速啟動標靶治療的作用。

精準醫療和伴隨診斷的擴展是另一個主要驅動力。自 1998 年 FDA核准首個曲妥珠單抗伴隨診斷以來，市場上與特定分子檢測相關的標靶治療數量不斷增加。例如，2012 年，FDA核准了cobas 4800 BRAF V600 突變檢測，用於指南黑色素瘤的Vemurafenib治療，為生物標記主導的癌症治療開創了先例。如今，自 2009 年 NCCN 指南更新以來，轉移性結直腸癌的 KRAS 突變檢測已被納入標準臨床實踐，使約 40% 的 KRAS 突變患者避免使用昂貴的抗 EGFR 療法。同樣，黑色素瘤的 BRAF 突變檢測確保只有具有 V600E 突變的患者才能接受Vemurafenib治療，從而提高反應率並減少不必要的藥物暴露。

液態切片因其非侵入性以及即時監測疾病動態的能力，正迅速成為腫瘤診斷的標準組成部分。 DiaCarta 的 RadTox 檢測計畫於 2023 年在佛羅裡達州推出，這是一種基於 cfDNA 的檢測方法，可測量化療和放射線治療週期之間的治療反應和腫瘤進展。這使腫瘤學家能夠在出現抗藥性時儘早調整治療策略，避免無效方案並減輕不利事件。 DiaCarta 也推出了其他腫瘤學專用檢測方法，包括用於膀胱癌復發監測的 Oncuria 和用於 BCG 治療反應預測的 Oncuria，以解決藥物短缺情況下的治療最佳化問題。該公司於 2022 年推出的 ColoScape 檢測可靈敏地檢測大腸直腸癌特異性甲基化模式和突變，從而能夠對晚期腺瘤患者進行早期療育。

Naveris 的 NavDx 檢測於 2020 年投入臨床，並於 2024 年初獲得美國醫療保險和醫療補助服務中心 (CMS) 的高級診斷檢測 (ADLT) 認證。 NavDx 可檢測血液中的腫瘤組織修飾病毒 (TTMV)-HPV DNA，從而能夠在出現臨床或影像學證據之前及早發現由 HPV 引發的癌症。 2024 年 7 月，加州藍盾保險公司 (Blue Shield of California) 開始承保 NavDx，擴大了這項非侵入性、高靈敏度檢測的覆蓋範圍。此項核保決定基於 30 多篇同行評審出版物的數據，這些出版物證明了 NavDx 在檢測分子殘留病灶和為 HPV 相關頭頸癌的監測策略提供資訊方面的效用。

現代分子診斷技術的營運效率也正在改變腫瘤學工作流程。儘管NGS仍然是全面基因組分析的黃金標準，但其較長的周轉時間可能會延遲侵襲性癌症的治療開始。基於PCR的快速檢測，例如2019年在美國推出的Idylla MSI檢測，可在當天檢測大腸直腸癌和其他癌症的MSI狀態，從而及時確定合格免疫治療。在2025年USCAP年會上，西奈山伊坎醫學院和梅奧診所的研究表明，Idylla™ MSI檢測與傳統方法高度一致，並有助於解決罕見子宮內膜癌亞型的分類差異。

從經濟角度來看，分子診斷與美國醫療保健系統向價值導向醫療的轉變相契合。轉移性大腸直腸癌的治療前KRAS檢測已被證明可以避免無效的抗EGFR治療，每年節省數億美元。同樣，像Oncuria這樣的預測性檢測可以確保將有限的卡介苗（BCG）等藥物分配給最有可能產生療效的患者，從而減少浪費並最大限度地提高臨床療效。

諸如2015年宣布的美國舉措計畫等大規模舉措，持續推動生物標記的發現和檢驗，進一步擴大了市場上可供檢測的標靶範圍。隨著NGS成本的下降和自動化程度的提高，人工智慧與分子診斷的整合，尤其是在腫瘤起源預測和抗藥性機制分析方面的應用，預計將提升臨床效用並加速其普及。伴隨診斷的監管支持、支付方對其臨床效用的認可，以及不斷成長的真實世界證據基礎，這些因素共同使分子診斷牢牢佔據了美國未來癌症治療的核心支柱地位，而2023-2025年將是市場擴張、技術成熟和廣泛臨床整合的關鍵時期。

目錄

第 1 章美國基於腫瘤的分子診斷市場：調查方法與範圍

第2章美國基於腫瘤的分子診斷市場：執行摘要

  • 市場概述
  • 類型和產品簡介
  • 技術簡介
  • 競爭格局簡介

第 3 章美國基於腫瘤的分子診斷市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 癌症發生率上升
    • 精準醫療簡介
    • 分子檢測技術的進展
  • 市場限制因素分析
    • 測試和設備高成本
    • 報銷和法律規範不一致
    • 資源貧乏地區的交通受限
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章美國基於腫瘤的分子診斷市場：類型估計和趨勢分析

  • 美國基於腫瘤的分子診斷市場：類型變異分析
  • 乳癌
  • 攝護腺癌
  • 大腸直腸癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 血癌
  • 腎癌
  • 其他

第5章美國基於腫瘤的分子診斷市場：產品估計與趨勢分析

  • 美國基於腫瘤的分子診斷市場：產品差異分析
  • 裝置
  • 試劑
  • 其他

第6章美國基於腫瘤的分子診斷市場：技術評估與趨勢分析

  • 美國腫瘤分子診斷市場：技術波動分析
  • PCR
  • 原位雜合技術
  • 惰性
  • 晶片和微陣列
  • 質譜法
  • 定序
  • TMA
  • 其他

第7章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 新模型發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2024年主要企業市佔率分析
  • 公司熱圖分析
  • 公司簡介
    • Abbott
    • Bayer AG
    • BD
    • Cepheid
    • Agilent technologies, inc.
    • Danaher
    • Hologic, Inc.
    • Qiagen
    • F. Hoffmann-La Roche Ltd.
    • Siemens
    • Sysmex
Product Code: GVR-4-68040-716-2

Market Size & Trends:

The U.S. oncology based molecular diagnostics market size was estimated at USD 1.49 billion in 2024 and is expected to grow at a CAGR of 5.2% from 2025 to 2033. Key market driving factors for the market include the rapid evolution of sequencing technologies (e.g., shift from Sanger to NGS, adoption of long-read platforms like Nanopore and SMRT), enabling high-throughput, comprehensive genomic profiling. Increased availability of targeted therapies and pan-cancer biomarkers (e.g., HER2, EGFR, NTRK fusions) fuels demand for companion diagnostics. Rising adoption of minimally invasive methods, such as liquid biopsy/ctDNA testing, supports real-time disease monitoring and early detection. Advances in high-sensitivity platforms like ddPCR and RNA-seq improve the detection of low-frequency mutations and fusions, while AI/ML integration enhances tumor origin prediction. The growing clinical utility across multiple tumor types-from lung adenocarcinoma to breast cancer-combined with regulatory approvals for large-panel CDx assays (e.g., FoundationOne CDx, MSK-IMPACT), further accelerates market growth.

The U.S. oncology-based molecular diagnostics (MDx) market is experiencing strong growth momentum, fueled by rapid technological advancements, increasing integration of precision medicine into routine cancer care, expanding payer coverage, and a steady rise in clinically validated biomarkers. Over the past decade, the market has evolved from single-gene, low-throughput assays such as Sanger sequencing to comprehensive, high-throughput next-generation sequencing (NGS) platforms capable of detecting a broad range of mutations, fusions, copy number variations, and microsatellite instability in a single workflow. This technological shift has shortened turnaround times, improved sensitivity, and allowed clinicians to make treatment decisions faster, directly impacting patient outcomes.

One of the most notable technological drivers is the adoption of rapid, fully automated platforms such as the Idylla system by Biocartis, which has steadily expanded its oncology test portfolio since its U.S. introduction in 2015. The Idylla KRAS Mutation Test (U.S. launch in 2016) and EGFR Mutation Test (U.S. launch in 2017) enabled same-day biomarker results directly from FFPE tissue without complex laboratory infrastructure. More recently, the Idylla GeneFusion Assay, launched in 2023 in the U.S., provided detection of ALK, ROS1, RET, and NTRK gene fusions as well as MET exon 14 skipping in non-small cell lung cancer (NSCLC) with a turnaround time of under 3 hours. At the USCAP 2025 Annual Meeting (March 22-27, 2025), multiple independent studies from institutions such as Memorial Sloan Kettering and MD Anderson Cancer Center confirmed high concordance between Idylla(TM) assays and NGS for KRAS, EGFR, and BRAF mutations, while highlighting Idylla's ability to identify additional clinically relevant mutations not detected by certain competitor panels. The platform's rapid testing of cytology supernatants and fine needle aspiration samples, which would otherwise be discarded, underscores its role in expanding testable specimen types and accelerating targeted therapy initiation.

The expansion of precision medicine and companion diagnostics is another major growth driver. Since the FDA approved the first companion diagnostic for trastuzumab in 1998, the market has seen an increasing number of targeted therapies tied to specific molecular tests. For example, in 2012, the FDA approved the cobas 4800 BRAF V600 Mutation Test to guide vemurafenib therapy in melanoma, establishing a precedent for biomarker-driven oncology treatment. Today, KRAS mutation testing in metastatic colorectal cancer-integrated into standard clinical practice since NCCN guideline updates in 2009-prevents the use of costly anti-EGFR therapies in the approximately 40% of patients who harbor KRAS mutations. Similarly, BRAF mutation testing in melanoma ensures that only patients with the V600E mutation are given vemurafenib, improving response rates and reducing unnecessary drug exposure.

Liquid biopsy is rapidly becoming a standard component of oncology diagnostics due to its non-invasive nature and ability to monitor disease dynamics in real time. DiaCarta's RadTox test, deployed statewide in Florida in 2023, is a cfDNA-based assay that measures treatment response and tumor progression between cycles of chemotherapy or radiotherapy. This allows oncologists to modify treatment strategies early in cases of resistance, avoiding ineffective regimens and mitigating adverse events. DiaCarta has also launched other specialized oncology assays such as Oncuria for bladder cancer recurrence monitoring and BCG therapy response prediction, addressing treatment optimization in the face of drug shortages. The company's ColoScape test, launched in 2022, detects methylation patterns and mutations specific to colorectal cancer with high sensitivity, enabling early intervention in patients with advanced adenomas.

Naveris' NavDx test, first clinically introduced in 2020 and designated an Advanced Diagnostic Laboratory Test (ADLT) by CMS in early 2024, represents another milestone in viral oncology diagnostics. NavDx detects Tumor Tissue Modified Viral (TTMV)-HPV DNA in blood, enabling earlier detection of HPV-driven cancers before clinical or imaging evidence emerges. In July 2024, Blue Shield of California began covering NavDx, expanding access to this non-invasive, highly sensitive test. The coverage decision was based on data from over 30 peer-reviewed publications demonstrating its utility in detecting molecular residual disease and informing surveillance strategies for HPV-related head and neck cancers.

The operational efficiency of modern molecular diagnostics is also transforming oncology workflows. While NGS remains the gold standard for comprehensive genomic profiling, its longer turnaround times can delay treatment initiation in aggressive cancers. Rapid PCR-based assays such as the Idylla MSI Test, launched in the U.S. in 2019, deliver same-day MSI status for colorectal and other cancers, enabling timely decisions on immunotherapy eligibility. At USCAP 2025, studies from Icahn School of Medicine at Mount Sinai and the Mayo Clinic demonstrated high concordance between Idylla(TM) MSI testing and traditional methods, with the added benefit of resolving classification discrepancies in rare endometrial carcinoma subtypes.

From an economic perspective, molecular diagnostics align with the U.S. healthcare system's shift toward value-based care. Studies showed that pre-treatment KRAS testing in metastatic colorectal cancer could save hundreds of millions of dollars annually by avoiding ineffective anti-EGFR therapy. Similarly, predictive tests such as Oncuria ensure that limited supplies of drugs like BCG are allocated to patients most likely to respond, reducing waste and maximizing clinical benefit.

Large-scale initiatives such as the U.S. Precision Medicine Initiative, announced in 2015, continue to drive biomarker discovery and validation, further expanding the market's testable targets. As NGS costs decline and automation improves, the integration of artificial intelligence into molecular diagnostics-particularly for tumor origin prediction and resistance mechanism analysis-is expected to enhance clinical utility and accelerate adoption. The combination of regulatory support for companion diagnostics, payer recognition of clinical utility, and an expanding body of evidence from real-world implementation solidifies molecular diagnostics as a central pillar in the future of oncology care in the U.S., with 2023 - 2025 marking a pivotal period of market expansion, technological maturation, and broader clinical integration.

U.S. Oncology Based Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. oncology based molecular diagnostics market report based on product, technology, type, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Kidney Cancer
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Reagents
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR
  • In situ hybridization
  • INAAT
  • Chips and microarrays
  • Mass spectrometry
  • Sequencing
  • TMA
  • Others

Table of Contents

Chapter 1. U.S. Oncology Based Molecular Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Product Segment
      • 1.1.1.3. Technology segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. U.S. Oncology Based Molecular Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Technology Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. U.S. Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising Cancer Prevalence
    • 3.4.2. Adoption of Precision Medicine
    • 3.4.3. Advances in Molecular Testing Technologies
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Costs of Testing and Equipment
    • 3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
    • 3.5.3. Limited Access in Low-Resource Regions
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. U.S. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Oncology Based Molecular Diagnostics Market: Type Movement Analysis
  • 4.2. Breast Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Prostate Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Colorectal Cancer
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Cervical Cancer
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Liver Cancer
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Lung Cancer
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Blood Cancer
    • 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Kidney Cancer
    • 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.3. Reagents
    • 5.3.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4. Others
    • 5.4.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

  • 6.1. U.S. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • 6.2. PCR
    • 6.2.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3. In situ hybridization
    • 6.3.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4. INAAT
    • 6.4.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Chips and microarrays
    • 6.5.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Mass spectrometry
    • 6.6.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. TMA
    • 6.8.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. New Type Launch
    • 7.2.2. Partnerships
    • 7.2.3. Acquisition
    • 7.2.4. Collaboration
    • 7.2.5. Funding
  • 7.3. Key Company Market Share Analysis, 2024
  • 7.4. Company Heat Map Analysis
  • 7.5. Company Profiles
    • 7.5.1. Abbott
      • 7.5.1.1. Company Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Type Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Bayer AG
      • 7.5.2.1. Company Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Type Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. BD
      • 7.5.3.1. Company Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Type Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Cepheid
      • 7.5.4.1. Company Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Type Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Agilent technologies, inc.
      • 7.5.5.1. Company Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Type Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Danaher
      • 7.5.6.1. Company Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Type Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Hologic, Inc.
      • 7.5.7.1. Company Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Type Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Qiagen
      • 7.5.8.1. Company Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Type Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. F. Hoffmann-La Roche Ltd.
      • 7.5.9.1. Company Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Type Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Siemens
      • 7.5.10.1. Company Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Type Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Sysmex
      • 7.5.11.1. Company Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Type Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 U.S. oncology based molecular diagnostics market, by Technology, 2021 - 2033 (USD Million)
  • Table 4 U.S. oncology based molecular diagnostics market, by Type, 2021 - 2033 (USD Million)
  • Table 5 U.S. oncology based molecular diagnostics market, by Product, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 U.S. Oncology based Molecular diagnostics market- Key market driver analysis
  • Fig. 7 U.S. Oncology based Molecular diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 U.S. Oncology based Molecular diagnostics market - Porter's analysis
  • Fig. 10 U.S. Oncology based Molecular diagnostics market - PESTEL analysis
  • Fig. 11 U.S. Oncology based Molecular diagnostics market Type outlook key takeaways
  • Fig. 12 U.S. Oncology based Molecular diagnostics market: Type movement analysis
  • Fig. 13 Breast Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Prostate Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Colorectal Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Cervical Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Liver Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Lung Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Blood Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Kidney Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Others Cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Oncology based Molecular diagnostics market product outlook key takeaways
  • Fig. 23 U.S. Oncology based Molecular diagnostics market: product movement analysis
  • Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Reagents market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Oncology based Molecular diagnostics market technology outlook key takeaways
  • Fig. 28 U.S. Oncology based Molecular diagnostics market: technology movement analysis
  • Fig. 29 PCR market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 In situ hybridization market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 INAAT market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Chips and microarrays market estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Mass spectrometry market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Sequencing market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 TMA market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Strategy framework